Promoter Ashwani Khemka Acquires More Sanjivani Paranteral Shares

Sanjivani Paranteral Limited announced that its Managing Director and promoter, Ashwani Khemka, acquired an additional 6,451 shares through open market transactions on March 27, 2026. This purchase brings his total shareholding to 36,32,102 shares. The acquisition represents a slight increase in his stake to 29.57% of the company's total voting capital, up from his previous holding of 29.51% (36,25,651 shares). The transaction was made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Stake Increase Signals Promoter Confidence

An increase in promoter shareholding, even if marginal, is often interpreted as a signal of confidence in the company's future performance and strategic direction. Khemka's latest acquisition reinforces his commitment to Sanjivani Paranteral's ongoing growth initiatives.

Background: Expansion Plans and Shareholding History

Ashwani Khemka has been a significant stakeholder in Sanjivani Paranteral for several years. He previously consolidated his ownership by acquiring a substantial 26% minority stake in September 2021. In more recent times, the company has focused on strategic expansion. Sanjivani Paranteral raised funds through warrant issuance to Khemka and a preferential allotment to other investors in December 2023 to support these growth plans. A key strategic move was the collaboration established in November 2023 with Hindustan Antibiotics Limited (HAL) for manufacturing IV formulations and IV sets, which includes the development of a new production facility. Historically, promoter holdings have fluctuated between approximately 27% and 31%, indicating Khemka's current stake remains within this established range.

Key Metrics

As of March 27, 2026, Ashwani Khemka holds 36,32,102 shares, representing 29.57% of Sanjivani Paranteral Limited's voting capital. The company's total equity share capital is reported at ₹1228.43 lakh (₹12.28 crore).

Looking Ahead

Future monitoring by investors will likely focus on any further shareholding adjustments by Khemka or other promoters. Tracking the progress of Sanjivani Paranteral's expansion plans, particularly the IV formulation plant collaboration with HAL, will be important. Additionally, observing the company's financial performance and revenue growth, especially as its manufacturing capabilities expand, will be key indicators.